AWARD A LETTER CONTRACT FOR RADX TECH - OASIS DIAGNOSTICS TO COMPLETE THE VALIDATION, APPROVAL, AND PRODUCTION PROCESSES IN ORDER TO SCALE UP CAPACITY

Oasis Diagnostics provides a series of innovative tools for standardized saliva acquisition including devices specific for cell free RNA / viral RNA that are ideally suited for COVID-19 testing on difficult saliva specimens. These collection tools [Pure•SAL, Super•SALâ"¢, Micro•SAL and SimplOFy] in particular are agnostic to the test being used and are already being used by many companies developing oral / saliva based tests for COVID-19. Oasis is a small business with under 20 employees and has been requested by companies developing COVID-19 to scale up manufacturing in order to produce volumes in excess of 100,000 Units of these technologies on a daily basis.  In order to be able to meet this goal, Oasis Diagnostics requires additional manpower, equipment and additional resources that it does not have at the present time.  As a result Oasis is seeking funding through the RADx Program to facilitate large scale manufacturing to meet the rapidly growing market for saliva collection technologies